NCIt definition : A fully human monoclonal antibody targeting the vascular endothelial growth factor
receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration,
olinvacimab specifically binds to VEGFR2, thereby preventing the binding of its ligand
VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor
nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase
expressed by endothelial cells, while VEGF is overexpressed in many tumors and is
correlated to tumor progression.;
UNII : VFH55IZ5VI;
CAS number : 2095504-49-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2095504-49-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;